Celltex has an experienced team of international and domestic scientists and medical professionals, who have been involved in extensive research and stem cell product development, including:
- confirming the safety, reliability and efficacy of the Company’s intellectual property
- continuing to refine standard operating procedures
- continuing to improve new methods of culturing, banking, expanding, processing and manufacturing stem cells
The team has expertise in stem cell research, medically-based technology and clinical trials, as well as applying for and receiving FDA clearances and operations in the United States and foreign countries.
The Company’s board of directors and business advisors support the Company’s management by providing professional business development and long-term strategic objectives.
David G. Eller
Co-Founder, Chairman & Chief Executive Officer
David G. Eller oversees the strategic vision of the private biotechnology company whose focus is on spearheading breakthroughs in regenerative medicine using autologous adipose derived mesenchymal stem cells for regenerative therapy.Read more about David
In over three decades, Eller has been at the helm of both privately and publicly held companies in the areas of biotechnology, life sciences, pharmaceutical manufacturing and bioscience research and development. He served as President of DuPont Pharmaceuticals Company – Europe; Strategic Advisor to the Chief Operating Officer of the E. I. du Pont de Nemours and Company (“The DuPont Company”); Chief Executive Officer and President of Virbac Corporation; and Founder, Chairman and Chief Executive Officer of Granada Corporation and American National Petroleum Corporation.
In addition, he served as a two-term Chairman of the Board of Regents of The Texas A&M University System, as well as simultaneously holding the position of Chancellor of The Texas A&M University System for a period. During his tenure, he established the Institute of Biosciences and Technology, located in the Texas Medical Center, and a number of additional bioscience programs, including establishing procedures for intellectual property commercialization.
Eller’s current and previous board leadership with medical, science and financial entities is widespread, including the Boards of Celltex Therapeutics Corporation, Baylor College of Medicine, DuPont Pharmaceuticals Company – Europe, the Foundation for Biomedical Research, Rice University Energy & Environmental Systems Institute, Memorial Hermann Hospital, Texas Chamber of Commerce, Allied Bancshares and First Interstate Bank, among others.
His career accomplishments have been recognized through numerous accolades. He received the Medallion of Entrepreneurship, Beta Gamma Sigma National Entrepreneur of the Year Award and the Enterprise Award for work in the biotechnology and life sciences fields.
Other honors include receiving the Paul Harris Award from Rotary International, and he is the first in the history The Texas A&M University System to receive the title of Chairman Emeritus. A major research building on the Texas A&M University campus was named in his honor – the David G. Eller Oceanography and Meteorology Building.
Eller is a graduate of Texas A&M University, the Stanford Graduate School of Business Executive Program, the Harvard Business School Advanced Management Program and the Stanford Business School Corporate Governance Program.
He served eight years as an officer on active duty and reserves in the United States Army, Corps of Engineers, as Commanding Officer, 541st Combat Engineer Company, 11th Engineer Group, 7th Army, Corps of Engineers – Schwetzingen, Germany.
Stanley C. Jones
M.D., Co-Founder, Director & Chief Medical Officer
Dr. Stanley Jones is an internationally-recognized spine surgeon with 45 years of experience. After receiving his B.A. in chemistry from Texas Tech University in 1965 and his M.D. from the University of Texas Southwestern Medical School in 1969, he completed an internship at the University of Utah before serving as Captain of the Medical Corps in the U.S. Army.Read more about Stan
Following his service in the military, he completed his orthopedic residency at the University of Texas Medical School in Houston and his fellowship at Wellesley Hospital in Canada. Dr. Jones is a licensed physician in the state of Texas and is certified by the American Board of Orthopedic Surgery.
As the founder and Medical Director of the Spine Care Center in Houston, he performs surgery and sees patients on a full-time basis. Dr. Jones’ operating privileges also extend outside his practice to Memorial Hermann Hospital Southwest, where he was previously Director of Spine Care Services, Houston Orthopedic and Spine Hospital and Elite Center for minimally invasive surgery.
Dr. Jones utilizes his experience and expertise to educate colleagues and peers through the publication of medical papers on back pain and surgical techniques and through seminars on numerous topics related to the spine. He has been a part of multiple research projects in partnership with institutions such as Johnson & Johnson, Bayer Pharmaceuticals and Abbott Spine.
Exchanging knowledge and research with likeminded physicians is important to Dr. Jones, which is why his involvement in highly-esteemed medical organizations is vast. In addition to being the Diplomat of the American Board of Orthopedic Surgery, he is also a member of the American Academy of Orthopedic Surgeons, the American Medical Association, the Texas Medical Association, the North American Spine Association, the International Intradiscal Therapy Society, the Anti–Aging Society, the Association of Ethical Spine Surgeons and the American Board of Spine Surgery.
In 2009, Dr. Jones suffered from a sudden onset of debilitating autoimmune psoriatic arthritis. Although he continued to see patients, his condition prevented him from performing surgery. When conventional treatments failed to provide him with relief, he located a company in Asia that had developed a state-of-the-art technology that allowed him to receive the treatment of autologous (his own) adult mesenchymal stem cells (MSCs). Four months after receiving stem cell therapy, he was able to return to a normal surgery schedule and a life without pain. As a result, he is responsible for bringing a proprietary stem cell technology to the United States to start Celltex Therapeutics Corporation in 2011 with David Eller.
His current interests are in the field of minimally invasive spine surgery, pain management and advocating for the use of adult autologous mesenchymal stem cells for medical benefits to patients.
John P. Wade
Director & Chief Financial Officer
John Wade, Senior and Managing Partner of Wade & Company, LLP, has more than 43 years of experience in public accounting and currently serves as the primary accountant and finance counsel for Celltex Therapeutics Corporation. After graduating with a Bachelor’s Degree in Business Administration and Accounting from Texas Christian University, he obtained his Doctorate of Jurisprudence from South Texas College of Law.Read more about John
Mr. Wade began his public accounting career in 1969 in the tax office of Arthur Andersen, LLP in Houston, where he worked for 11 years, building a substantial client base of corporations, trusts and individuals. In 1984, Mr. Wade formed Wade & Company and served as president for 20 years before changing the company to Wade & Company, LLP in 2004 and becoming senior and managing partner. The firm specializes in representing high-net-worth individuals, estates and trusts, and major corporate clients in all phases of tax, financial and business tax matters.
Throughout his career, Mr. Wade has provided solutions to a wide variety of tax problems and counseled private and public companies regarding general business and tax planning matters. His tax practice involves general and domestic tax planning with an emphasis on mergers and acquisitions, choice of entity considerations and corporate finance transactions. Mr. Wade works with Celltex’s executive leadership team on corporate formations and reorganizations, partnership formations and regulations, and tax compliance and saving strategies.
Mr. Wade is licensed by the State Bar of Texas and the Texas State Board of Public Accounting and is a member of several industry-leading organizations, such as the American Institute of Certified Public Accountants, the Texas and Houston Society of Certified Public Accountants and the Houston Bar Association.
Lawrence R. Samuels
Lawrence (Larry) Samuels has more than 40 years of experience in corporate services law. Currently he serves as General Counsel for Celltex Therapeutics Corporation. After earning his B.A. in Political Science from the University of Chicago (1968), he received his Juris Doctor degree from Harvard University Law School in 1971. As General Counsel for Celltex, Mr. Samuels advises management on all aspects of legal and regulatory matters and works directly with senior management in the area of acquisitions.Read more about Larry
Mr. Samuels’ career began at the law firm Cravath, Swaine and Moore in New York City where he focused on business law prior to joining what is now known as McGuire Woods in 1987. Before retiring from McGuire Woods in 2013, he was a partner at McGuire Woods (and its predecessor firm Ross & Hardies) where he practiced corporate law and also served as outside General Counsel for several public companies.
Throughout his career, Mr. Samuels has represented companies from a number of countries, including Japan, Great Britain, France, Germany and Australia, for which he handled international transactions related to U.S. acquisitions, operations and investments. He also represented U.S. companies on matters of foreign acquisitions in Europe, Latin America and Asia.
Mr. Samuels serves as a Board Advisor to the U.S. Chamber of Commerce Foundation and BiOWiSH Technologies, Inc. His fields of expertise include: commercial and securities litigation, mergers and acquisitions, international transactions, securities regulation, corporate finance and corporate governance.
Dr. Nabil Sakkab has over forty years of experience in the fields of science and business. He is a 1970 graduate of the American University of Beirut with a Bachelor’s Degree in Chemistry. In 1974, he joined Procter & Gamble in Cincinnati, Ohio, following a doctorate in chemistry from the Illinois Institute of Technology in 1973 and post doctorate studies at Texas A&M University.Read more about Nabil
Dr. Sakkab retired from Procter & Gamble in 2007 as Senior Vice President, Corporate Research and Development following several assignments in Cincinnati, Brussels, Belgium and Kobe, Japan, on a variety of businesses, including OTC Health Care and Household Products. He served on P&G’s Leadership Council and the Innovation Committee of P&G’s Board of Directors.
He is a thought leader and worldwide speaker in the Open Innovation movement, the author of several scientific and innovation Management publications, and co-inventor on more than 27 patents. Dr. Sakkab was awarded the 2007 IRI Medal for Leadership in R&D Management and the 2007 Holland Award for best article in Innovation Management.
Dr. Sakkab served on the Boards of IRI, CEFIC, CEFIC Research & Science and Greenearth Company while working for Procter & Gamble and is an Advisory Professor for Tsinghua University in Beijing. Currently he serves on the Board of Directors of Celltex Therapeutics Corporation, as well as the Boards of Altria and Givaudan, two major enterprises, and three additional companies in biotechnology and health care: PharNext, BiOWiSH Technologies and Deinove.